Life Science Players Join €23m European Project for Precision Medicine, PRECISEU
The European project PRECISEU (PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope) aims to accelerate the development and adoption of personalised medicine in Europe by connecting institutions with a specific focus on advanced therapy medicinal products (ATMPs).
It is funded by the European Commission's Horizon fund, whose contribution is approximately €11 million to the total €22.7 million budget. The Horizon programme has put aside €95.5 billion for science and tech projects in Europe.
"With a budget of EUR 95.5 billion, and a set of modern instruments, Horizon Europe will be an extremely powerful and world-leading research and innovation programme," said Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth.
PRECISEU is co-ordinated, by the Catalonian public-private foundation BioCat which was set up in 2006 by the Government of Catalonia and the Barcelona City Council. The project brings together 25 partners across 11 participating states: Spain (6), Germany (2), Romania (3), Bulgaria (2), Italy (3), Belgium (2), Lithuania (1), Sweden (2), the Netherlands (1), Greece (2), Ukraine (1).
Kicking off with a meeting at the Palace of the Government of Catalonia, key players of the PRECISEU project are set to present on 10 July 2024. These include consortium representatives from the European Commission, regional authorities, medical centres, and pharma companies like AstraZeneca who recently set up a headquarters in Barcelona. They will discuss how the project, which is expected to run until 2029, will deliver the advancement of precision and personalised medicine across its five years.
Map of the participants in the PRECISEU collaboration. Credit: BioCat
Sweden has become the most recent nation to announce their participation in the collaboration. Sahlgrenska Science Park and Business Region Göteborg (BRG) have joined the initiative in collaboration with Region Västra Götaland and Sahlgrenska University Hospital. Both are expected to take leading roles.
Sahlgrenska Science Park will focus on market access, industry growth, and patient accessibility. Their CEO, Cecilia Edebo, said: "We are proud to represent Sweden and actively contribute to this strategically important international project. Developing a roadmap and collaboration model to advance precision medicine at the European level places us at the forefront of shaping the future of healthcare.”
Existing ATMP hubs and capabilities will be mapped by Business Region Göteborg. Patrik Andersson, their CEO, commented: "Engaging in this consortium aligns perfectly with our vision to foster a dynamic and innovative business environment in West Sweden."
He continued: "The project's focus on advanced therapies and health data integration is particularly exciting and promising for our region. This initiative alongside the establishment of CCRM Nordic in Gothenburg further solidifies Gothenburg's position as a leading hub for life science and health innovation."
Related Resources
